Postoperative Recurrence Risk and Associated Factors in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy
Sponsor study identifier
observational
100
1 country
1
Study Start
October 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This observational study aims to understand the risk of cancer returning after surgery in people with esophageal squamous cell carcinoma, a type of cancer of the food pipe. It focuses on people who received immunotherapy and chemotherapy before surgery. Researchers will review existing medical records, scans, reports on tissue removed during surgery, and follow-up information. They will examine when and where cancer returns and which patient characteristics, treatment details, scan findings, and tissue findings are associated with its return. All treatment and tests were part of routine care. The study does not assign treatment or require additional scans, tissue collection, or follow-up visits.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 14, 2026
Actual (reported)September 16, 2026
Actual (reported)October 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Recurrence-Free Survival
Time, in months, from surgery to the first documented local, regional, or distant recurrence, determined using imaging, pathology, or documented clinical assessment. Participants without recurrence will be censored at their last disease assessment. Death without documented recurrence is not an RFS event; these participants will be censored at their last disease assessment before death. RFS probabilities at 12 and 24 months after surgery will be estimated using the Kaplan-Meier method.
From surgery through December 1, 2025, up to 64 months.
Patients with histologically confirmed esophageal squamous cell carcinoma who underwent curative esophagectomy between August 1, 2020, and October 31, 2025, after neoadjuvant immunochemotherapy. Existing clinical records, FDG PET/CT findings, surgical pathology reports, and postoperative follow-up records will be reviewed to assess recurrence risk and associated factors. All treatments and examinations were provided as part of routine clinical care and were not assigned by this study.
The source population comprises adults who underwent esophagectomy for esophageal squamous cell carcinoma at the study institution between August 1, 2020, and October 31, 2025. Patients will be identified through institutional medical records, imaging archives, surgical and pathology registries, and existing follow-up records. All patients within this surgical window who received neoadjuvant immunochemotherapy and meet the eligibility criteria will be included. No random sampling will be performed. Documented postoperative outcomes will be reviewed through December 1, 2025.
Peking University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
First Submitted
September 14, 2026
First Posted
September 16, 2026
Study Start
October 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 1, 2026
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 16, 2026
Record last verified: 2026-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: